Seguir
Neil Osheroff
Neil Osheroff
Professor of Biochemistry, Vanderbilt University School of Medicine
Dirección de correo verificada de Vanderbilt.Edu
Título
Citado por
Citado por
Año
Mechanism of quinolone action and resistance
KJ Aldred, RJ Kerns, N Osheroff
Biochemistry 53 (10), 1565-1574, 2014
13492014
Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme
DA Burden, N Osheroff
Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression 1400 (1-3 …, 1998
7881998
Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism (∗)
SJ Froelich-Ammon, N Osheroff
Journal of Biological chemistry 270 (37), 21429-21432, 1995
7431995
In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction.
M Berrios, N Osheroff, PA Fisher
Proceedings of the National Academy of Sciences 82 (12), 4142-4146, 1985
6641985
Etoposide, topoisomerase II and cancer
EL Baldwin, N Osheroff
Current Medicinal Chemistry-Anti-Cancer Agents 5 (4), 363-372, 2005
6532005
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing
JE Deweese, N Osheroff
Nucleic acids research 37 (3), 738-748, 2009
5322009
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice
JM Fortune, N Osheroff
Academic Press 64, 221-253, 2000
5092000
DNA topoisomerase II, genotoxicity, and cancer
AK McClendon, N Osheroff
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 623 (1 …, 2007
5082007
DNA topoisomerase II from Drosophila melanogaster. Relaxation of supercoiled DNA.
N Osheroff, ER Shelton, DL Brutlag
Journal of Biological Chemistry 258 (15), 9536-9543, 1983
4091983
Biochemical basis for the interactions of type I and type II topoisomerases with DNA
N Osheroff
Pharmacology & therapeutics 41 (1-2), 223-241, 1989
3841989
DNA topoisomerase II in therapy-related acute promyelocytic leukemia
AR Mistry, CA Felix, RJ Whitmarsh, A Mason, A Reiter, B Cassinat, ...
New England Journal of Medicine 352 (15), 1529-1538, 2005
3382005
Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage
JM Fortune, N Osheroff
Journal of Biological Chemistry 273 (28), 17643-17650, 1998
3361998
Catalytic function of DNA topoisomerase II
N Osheroff, EL Zechiedrich, KC Gale
BioEssays 13 (6), 269-275, 1991
3341991
Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide
N Osheroff
Biochemistry 28 (15), 6157-6160, 1989
3311989
Eukaryotic topoisomerases recognize nucleic acid topology by preferentially interacting with DNA crossovers.
EL Zechiedrich, N Osheroff
The EMBO journal 9 (13), 4555-4562, 1990
3211990
Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro.
P Ackerman, CV Glover, N Osheroff
Proceedings of the National Academy of Sciences 82 (10), 3164-3168, 1985
2961985
When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs
AH Corbett, N Osheroff
Chemical Research in Toxicology 6 (5), 585-597, 1993
2941993
Eukaryotic topoisomerase II. Characterization of enzyme turnover.
N Osheroff
Journal of Biological Chemistry 261 (21), 9944-9950, 1986
2871986
Topoisomerase II and leukemia
MJ Pendleton, RH Lindsey Jr, CA Felix, D Grimwade, N Osheroff
Annals of the New York Academy of Sciences 1310 (1), 98-110, 2014
2372014
Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes
AM Wilstermann, N Osheroff
Current topics in medicinal chemistry 3 (3), 321-338, 2003
2292003
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20